

February 12, 2026

To Shareholders,

Company Name: Renascience Inc.
Representative: Toshio Miyata, Chairman and CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

**Announcement of the Conclusion of XPRIZE Healthspan Clinical Trial Agreement (CTA)
with the King Abdullah International Medical Research Center (KAIMRC) in Saudi Arabia**

We are pleased to announce that we have concluded the Clinical Trial Agreement (the "CTA") with the King Abdullah International Medical Research Center (King Abdullah International Medical Research Center¹⁾), a medical research institution of the Government of Saudi Arabia (hereinafter "KAIMRC"), regarding the initiation of XPRIZE Healthspan²⁾ clinical trials using a PAI-1 inhibitor RS5614.

We have been advancing research and business development of the PAI-1 inhibitor RS5614 in fields of oncology and anti-aging/longevity through collaboration with domestic and international research and/or medical institutions.

This CTA was concluded as part of concrete initiatives based on the Memorandum of Understanding (the "MOU") executed in October 2025 with KAIMRC (as disclosed in the press release dated October 9, 2025, "Announcement of the conclusion of a Memorandum of Understanding with the King Abdullah International Medical Research Center in Saudi Arabia"). Under this CTA, KAIMRC will participate in our team and start both semi-final and final studies for the XPRIZE Healthspan.

1. Background and Purpose of the CTA

Based on anti-aging and longevity benefits of plasminogen activator inhibitor (PAI)-1 inhibitor RS5614, which the Company has been developing for many years, the Company applied to the XPRIZE Healthspan, a global competition for longevity, with the concept of "a new small molecule drug (oral drug) that removes senescent cells and suppresses aging-related diseases without promoting carcinogenesis" (Senolytic drug³⁾). The Company was selected as one of the Top 40 semi-finalists in May 2025 and initiated a semi-final clinical trial in August 2025 in collaboration with domestic research and/or medical institutions, including Tohoku University, Tokai University, and Hiroshima University (as disclosed in the press release dated August 18, 2025, "Announcement of the Initiation of the XPRIZE Healthspan Semi-Final Clinical Trial (Specified Clinical Research)"). Based on the results of the semi-final trial, the Top 10 finalists are to be selected around the fall of 2026 with prize money of USD 1 million, followed by a four-year final

clinical study for the final competition.

Saudi Arabia is promoting an economic reform initiative known as “Saudi Vision 2030⁴⁾”, which aims to reduce dependence on oil and diversify economic activities. A key goal of the Saudi Vision 2030 healthcare sector is to improve the productivity, quality, and efficiency of the healthcare system and thereby enhance the quality of human life in Saudi Arabia. KAIMRC is a core public research institute for biomedical and clinical research in Saudi Arabia, working in partnership with Saudi Arabian government agencies, such as the Ministry of Investment of Saudi Arabia (MISA⁵⁾), the Saudi Authority for Intellectual Property (SAIP⁶⁾), and the Saudi Food and Drug Authority (SFDA⁷⁾). KAIMRC promotes seamless integration into the country's biotechnology ecosystem and supports commercialization, technology transfer, and long-term partnerships aligned with the Saudi Vision 2030 initiative. KAIMRC is also part of the King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and is also a medical institution under the Ministry of National Guard-Health Affairs, which operates an extensive medical network throughout Saudi Arabia, including specialized hospitals, transplant centers, and primary and tertiary care facilities.

2. Overview of the CTA

(1) Target clinical trials

Semi-final and final clinical trials for the XPRIZE Healthspan competition

(2) Trial site

King Abdullah International Medical Research Center (KAIMRC)

(3) Costs

CTA stipulates the handling of costs required for clinical trials and distribution conditions in the event of receiving XPRIZE awards.

3. Future Outlook

There is currently no impact on the financial results for the fiscal year ending March 2026, but we will promptly disclose any matters that need to be disclosed in the future.

¹⁾ The King Abdullah International Medical Research Center (KAIMRC)

The King Abdullah International Medical Research Center (KAIMRC) is a leading institution for biomedical and clinical research in Saudi Arabia. KAIMRC provides world-class infrastructure, scientific expertise, and strategic guidance to support innovators and biotech companies from around the globe as they enter the Saudi market. Through close collaboration with government stakeholders, KAIMRC facilitates seamless integration into the national biotechnology landscape. This approach promotes commercialization, knowledge transfer, and long-term partnerships aligned with Saudi Vision 2030.

²⁾ XPRIZE Healthspan

Sponsored by the Saudi Arabian Hevolution Foundation⁸⁾ and others, this is a competition organized by the XPRIZE Foundation with the goal of revolutionizing the treatment approach to human aging and longevity and actively extending healthy lifespan by 10 years or more. The competition will award a total of 100 million US dollars to research teams that can extend healthy lifespan by 2030.

³⁾Senolytic drug

Senolytic drug is a drug that suppresses aging-related diseases without promoting carcinogenesis. The word is a combination of senescence and lytics.

⁴⁾ Saudi Vision 2030

Announced in 2016, this is a national strategy for Saudi Arabia, a national reform plan set forth by the Saudi Arabian government with the aim of breaking away from dependence on oil and diversifying the economy and society. It actively promotes international collaboration and investment in a variety of fields, including medicine, science and technology, tourism, and education.

⁵⁾ The Ministry of Investment of Saudi Arabia (MISA)

The Ministry of Investment of Saudi Arabia (MISA) is the Kingdom's lead agency for investment, cultivating a robust, business-friendly ecosystem and ensuring investors are supported at every step of their journey. Guided by Saudi Vision 2030, its mission is to promote Saudi Arabia as a world-class investment destination, attract and expand investments for sustainable economic growth, and help diversify the economy beyond oil. The ministry prioritizes high-impact sectors—such as a healthcare, biotechnology, and technology—to drive innovation and economic diversification, while forging international partnerships that position Saudi Arabia at the forefront of the global investment landscape

⁶⁾ The Saudi Arabian Authority for Intellectual Property (SAIP)

The Saudi Arabian Authority for Intellectual Property (SAIP) is a Saudi Arabian government agency responsible for intellectual property rights, including patents, trademarks, and copyrights. It also participates in domestic and international intellectual property policies and international frameworks, contributing to the development of the knowledge economy.

⁷⁾ Saudi Food and Drug Authority (SFDA)

This is the government agency responsible for the approval and review of food and drug products in Saudi Arabia. It is equivalent to the US Food and Drug Administration (FDA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

⁸⁾Hevolution Foundation

This foundation was Launched in 2021 in Saudi Arabia and is a global non-profit organization that provides grants and early-stage investments to incentivize independent research and

entrepreneurship in the emerging field of healthspan science. Vision: is to extend healthy lifespan for the benefit of all humanity. Mission: is to drive efforts to extend healthy human lifespan and understand the processes of aging, leveraging a broad set of tools through diverse approaches. In particular this foundation aims to:

- Increase the number of safe and effective treatments entering the market
- Compress the timeline of drug development, using the latest tools and technologies
- Increase accessibility to therapeutics that extend healthy lifespan